Sep 11, 2021 by Kody KesterHow Keytruda's Latest Approval in China Boosts MerckKeytruda received its second regulatory approval in China for the treatment of esophageal cancer.
Sep 11, 2021 by Kody KesterThese Promising Clinical Results Could Be Huge for Amgen InvestorsNew data from the phase 3 trial of tezepelumab bodes well for the drug candidate becoming a significant revenue producer in the near future.
Sep 10, 2021 by Kody KesterCould This Be Pfizer's Next Blockbuster Vaccine?Pfizer isn't resting on the laurels of its COVID vaccine success.
Sep 10, 2021 by Kody KesterCould This Game-Changing FDA Approval Mean Profit for Johnson & Johnson Shareholders?Johnson & Johnson's Invega Hafyera was approved by the FDA as the first and only twice-yearly injectable treatment for schizophrenia.
Sep 9, 2021 by Kody KesterCould This Label Expansion Be a Blockbuster for AbbVie's Shareholders?The EC's approval of Rinvoq for moderate to severe eczema is another step in the right direction for the company.
Sep 9, 2021 by Kody KesterMerck Investors Have Reason to Cheer This Label ExpansionThe biopharma company announced that it received two more approved indications for Keytruda in Japan.
Sep 5, 2021 by Kody KesterWilliams-Sonoma Knows How to Treat Its ShareholdersThis specialty retailer handed out its second dividend hike of the year and authorized a new, larger share repurchase program.
Sep 4, 2021 by Kody KesterAstraZeneca Enters Another Major Market With This IndicationThe pharma giant recently received approval to market Forxiga as a treatment for chronic kidney disease patients in Japan.
Sep 2, 2021 by Kody KesterIs This Medical-Device-Making Dividend Aristocrat a Buy?Medtronic met analysts' consensus revenue estimate and exceeded earnings forecasts in the first quarter of its fiscal 2022.
Aug 31, 2021 by Kody KesterIs This Monthly Dividend Payer a Buy?Realty Income is one of the steadiest publicly traded REITs, and growth should accelerate with record acquisitions set for this year.
Aug 30, 2021 by Kody KesterDoes the Pullback in This Pharma Stock Create a Buying Opportunity?Amgen continues to face the headwind of patient visits that are lower than before the pandemic.
Aug 29, 2021 by Kody KesterHere's What This Label Expansion Could Mean for Eli Lilly InvestorsThe pharmaceutical company's type 2 diabetes drug Jardiance was recently approved by the FDA for another indication.
Aug 29, 2021 by Kody KesterCould These Clinical Results Mean Profit for AbbVie Shareholders?The pharma stock announced strong phase 3 results for atogepant in the preventive treatment of episodic migraine.
Aug 27, 2021 by Kody KesterThis Potential Indication Could Mean Profit for Eli Lilly InvestorsEli Lilly updated investors on its ongoing phase 3 trials to treat patients who have moderate to severe eczema with a new drug.
Aug 25, 2021 by Kody KesterShould You Buy the Dip in This Pet Insurer?Trupanion reported a mixed second quarter with a revenue beat and an EPS miss.
Aug 22, 2021 by Kody KesterIs This Unsinkable REIT a Buy?National Retail Properties offers a safe, dependable 4.5% dividend yield.
Aug 22, 2021 by Kody KesterWhat This Label Expansion Means for MerckThe Keytruda-Lenvima combo was recently approved for its second oncology indication.
Aug 21, 2021 by Kody KesterHere's How This Vaccine Approval From the FDA Benefits PfizerHint: It's not the anticipated FDA approval of Pfizer and BioNTech's COVID vaccine.
Aug 20, 2021 by Kody KesterHere's What Recent News From the FDA Means for AstraZenecaEven though AstraZeneca and FibroGen must now conduct an additional safety trial to have a chance at FDA approval, not all is lost.
Aug 18, 2021 by Kody KesterWhile Others Have Struggled, This REIT Has Held Its OwnAfter a year of being affected by the COVID-19 pandemic, STORE Capital is ready to return to growth.
